BioSolution Acquires Additional Helixmith Shares Worth 3.4 Billion KRW

BioSolution announced on the 5th that it will additionally acquire 936,066 shares of its subsidiary Helixmith, which is engaged in medical and pharmaceutical research and development, for approximately 3.4 billion KRW.

After the stock acquisition, BioSolution's stake in Helixmith will be 16.8%. The scheduled date for the stock acquisition is April 25 of this year.

BioSolution stated that the purpose of this stock acquisition is to "maximize corporate value through additional share acquisition."